Borrowing of information across patient subgroups in a basket trial
  based on distributional discrepancy by Zheng, Haiyan & Wason, James M. S.
Borrowing of information across patient subgroups in a
basket trial based on distributional discrepancy
HAIYAN ZHENG1,∗, JAMES M.S. WASON1,2
1Biostatistics Research Group, Institute of Health of Society, Newcastle University, U.K.
2Hub for Trials Methodology Research, MRC Biostatistics Unit, University of Cambridge, U.K.
∗Email: haiyan.zheng@newcastle.ac.uk
Abstract
Basket trials emerge as a new class of efficient approaches to evaluate a treatment in several patient
subgroups simultaneously. In this paper, we develop a novel analysis methodology for early phase basket
trials, which enables borrowing of information to improve decision making in a collection of disjoint
subgroups. For each subgroup-specific parameter that underpins the treatment effect, a marginal
predictive prior (MPP) is specified using information from the other subgroups. More specifically, it
comprises a series of commensurate predictive priors (CPPs), each with a normal precision that captures
the commensurability of information. We propose using a distributional discrepancy to characterise the
commensurability of any subgroup pairs, so as to allow information sharing through a spike-and-slab
prior to be placed on the normal precision. When there exist at least three subgroups in a basket trial,
we convert the pairwise discrepancy measurements into a set of weights and allocate them to the CPPs
accordingly. This leads to an MPP that leverages only information from the most consistent subgroups.
The MPP is then updated using the contemporary subgroup data to a robust posterior. Operating
characteristics of the proposed methodology are evaluated through simulations motivated by a real
clinical trial. Compared with alternative Bayesian analysis models, our proposal is more advantageous
for (i) identifying the most consistent subgroups, and (ii) gauging the amount of information to be
leveraged from specific sources. Numerical results also suggest that our analysis methodology can
potentially improve the precision of estimates and the statistical power for hypothesis testing.
Key words: Basket trials; Hellinger distance; Hierarchical models; Precision medicine; Robustness.
1 Introduction
There has been an increasing interest in precision medicine (Mirnezami et al., 2012; Schork, 2015) over
the past few decades. Rapid advances in genomics and biomarkers allow stratification of patients into
subgroups that may have different benefit from new treatments. Unlike the one-size-fits-all concept in
conventional paradigms of clinical drug development, the aim of precision medicine is to target the right
treatments to the right patients at the right time. In the era of precision medicine, new trial designs have
been developed, several of which are examples of master protocols (Woodcock and LaVange, 2017; Renfro
and Mandrekar, 2018) to study multiple diseases or multiple agents, or sometimes both. One well known
class of master protocols is basket trials (Renfro and Sargent, 2017). In the simplest formulation, basket
trials evaluate a single targeted agent to patients that share a common feature but may present various
disease subtypes. It is administratively more efficient to plan a basket trial than a number of separate tri-
als for the small subgroups, respectively. Moreover, advantages also include addressing multiple research
questions simultaneously, for instance, which subgroup(s) of patients may benefit and to what extent.
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When analysing early phase basket trials, one major concern is the potential heterogeneity of the
treatment effect in various patient subgroups. Investigators are faced with the dilemma of discarding or
incorporating data from other subgroups to reach a decisive conclusion about the treatment effect for a
specific subgroup. The option of using concurrent information from other subgroups is intriguing, as it
may lead to considerable increase in the statistical power of the study. This should be balanced with the
risk that treatment effect in an important patient subgroup may be overlooked or missed. Conventional
analysis strategies such as stand-alone analyses (also known as the approach of no borrowing) and com-
plete pooling irrespective of subgroup labels have been criticised. Some authors propose using hierarchical
models, as a compromise between the two limiting opinions, to enable borrowing of information across
subgroups (Thall et al., 2003; Thall and Wathen, 2008; Berry et al., 2013). Such well-established approach
of borrowing is based upon the classical concept of exchangeability (Bernardo, 1996): it acknowledges that
the magnitude of clinical benefit may differ, but nothing is known a priori to suppose patients of some
subgroups benefit better than others. Neuenschwander et al. (2016) disucss a robust extension to the
standard hierarchical models by including the possibility of non-exchangeability for each parameter (vec-
tor) that underpins the clinical benefit in a subgroup. Their approach permits an extreme subgroup not
to be overly influenced by other subgroups in situations of data inconsistency.
Additional concerns about the subgroup effect are essential in precision medicine. Often, the targeted
therapy is effective only in some subgroups, and certain subgroups illustrate more similar clinical benefit
between themselves than with others. Several variations of standard hierarchical modelling have been
considered suitably for the context of basket trials to implement borrowing of information (Liu et al.,
2017; Chu and Yuan, 2018). Modifications are motivated mainly by (i) justification about plausible clus-
tering of similar subgroups, and (ii) quantification about the magnitude, to which a subgroup-specific
parameter should be shrunk towards the population mean. Most recently, more sophisticated methods in
the framework of Bayesian model averaging (Madigan and Raftery, 1994; Draper, 1995) have been applied
to analysing basket trials. Psioda et al. (2019) average over the complete model space, which is constituted
by all models for possible configurations of the subgroups that may demonstrate the same or disparate
efficacy. In a model that assumes identical treatment effect among certain subgroups, information is
pooled across the corresponding subgroups under the assumption of interpatient exchangeability. The
number of models to be included in the complete model space for averaging increases exponentially with
the number of subgroups involved in the basket trial. Hobbs and Landin (2018) enumerate all possible
subgroup pairs, wherein the parameters are considered to be either exchangeable or non-exchangeable.
Instead of considering the prior probability of an individual model for a subgroup pair to be true, they
use the product of prior probabilities that the parameters of each subgroup pair being exchangeable or
not. This can greatly reduce the computational complexity, compared with conventional Bayesian model
averaging.
To date, analysis methods for basket trials have predominantly been proposed in oncology, where each
subtrial testing the treatment in a specific subgroup is single-arm with a binary endpoint. In this paper,
we propose methodology motivated by a randomised, placebo-controlled phase II basket trial, which is be-
ing undertaken in patients of several related conditions that share symptoms. Clinical efficacy attributed
to the treatment in every subtrial is recorded on a continuous outcome. We build our work upon com-
mensurate priors (Hobbs et al., 2011, 2012) for parameters of a general linear model. The commensurate
priors approach can be seen as a special kind of hierarchical modelling, which is more advantageous for
leveraging external information in situations of just a few relevant studies. Using it can facilitate the
inferences with respect to all possible pairwise borrowing of information between K subgroups involved
in a basket trial, according to a formal assessment of information commensurability.
Given any subtrial information external to the one of analysis interest, a commensurate prior can be
specified. Specifically, it is a normal predictive prior centred at the external subtrial data parameter, with
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a precision parameter to capture the commensurability of the treatment effect that underpins the exter-
nal and contemparory subtrials. We explore an empirical choice of the spike-and-slab prior (Mitchell and
Beauchamp, 1988) to be placed on the precision parameter, which determines the degree of borrowing. For
overcoming prior-data conflict, we propose using a distributional discrepancy measure to characterise the
commensurability of information between any two subtrials. It could quantify the probability mass to be
placed on the “spike” prior for strong borrowing, and that on the “slab” prior for discounting inconsistent
information from an external subtrial, respectively. This discrepancy measure meanwhile discerns the ex-
ternal subtrials (when at least three subgroups are involved) according to their relative commensurability,
and can therefore encourage differential borrowing of information for inferences of the model parameter
specific to a subtrial. The proposed analysis methodology for information sharing is fundamentally differ-
ent from the existing approaches. It avoids the limiting assumption about exchangeability for parameters
of certain or all subgroups, but the distributional discrepancy measure informs the one-to-one borrow-
ing from each external subgroup. In contrast to the Bayesian model averaging strategies, our approach
presents great simplicity particularly when the investigation involves a large number of subgroups.
The remainder of this paper is structured as follows. We describe the motivating example and decision
criteria in Section 2. In Section 3, we present our analysis methodology and discuss how a discrepancy
measure may help make appropriate use of basket trial data. In Section 4, we perform a simulation study
to evaluate the operating characteristics of phase II basket trials that would have been analysed using
the proposed methodology, and compare our Bayesian model with some alternative analysis models. We
close with a discussion of our findings and future research arising in Section 5.
2 Motivating example and notation
We use a randomised, placebo-controlled phase II basket trial, as a motivating example, which evaluates
a new treatment for cognitive dysfunction in patients of primary biliary cholangitis (PBC) and Parkin-
son’s disease (PD). This clinical trial is led by Newcastle University; at the time of writing, it has been
funded but not yet opened to participants. Patients are to be recruited and stratified into three disjoint
subgroups, representing different clinical conditions. The PBC and PD basket trial thus comprises of
three subtrials, which hereafter will be referred to as modules. A continuous outcome measuring cognitive
performance will be used as the clinical endpoint in each module. Once the trial begins, patients of each
module will be randomised to receive either the new treatment or a placebo.
Letting k = 1, . . . ,K index the modules, we suppose there are nk patients recruited in module k. The
binary indicator with respect to the treatment assignment is denoted by Tik for patient i, i = 1, . . . , nk.
Specifically, Tik = 1 if patient i in module k was allocated to treatment and 0 if placebo. The trial data
collected from patient i of module k comprise some covariates denoted by zik = {zik1, . . . , zikp}, and a
post-treatment outcome of clinical interest, denoted by yik. The trial data can be fitted with a linear
regression model given by:
E(yik|zik, Tik) = z′ikγk + Tikθk, (1)
where γk is a (1×p) coefficient vector representing the main effects of the covariates. We are interested in
estimating the parameter θk that underpins the treatment effect in patients from a specific module, since
within each module
E(yik|zik, Tik = 1) = z′ikγk + θk,
E(yik|zik, Tik = 0) = z′ikγk
leads to an estimator of the treatment effect over a placebo, denoted by ∆(Tik) = θk.
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The principal aim of this basket trial is to estimate the treatment effect per module. A more accurate
estimate for θk helps to support the decision as to whether a phase III trial of the treatment should go
ahead, and in which patient subpopulation(s). Moreover, inferences based on evidence of the basket trial
can inform the design of a future trial, such as computing the sample size to sufficiently power the trial.
With respect to either continuing or halting the clinical evaluation, trial decisions per module can be
framed as a decision between Go and No-go. For cases where the randomised basket trial is analysed in
a Bayesian framework (Spiegelhalter et al., 1994), we follow Freedman et al. (1984) and consider testing
the hypothesis of treatment effect that corresponds to a range of null θk’s in each module:
H0 : θk ≤ 0 versus Ha : θk > 0.
In addition, a threshold δU will be needed to represent the magnitude of improvement required to conclude
the new treatment is sufficiently promising to warrant further trials. It is not uncommon to set δU a value
greater than 0. Conclusions may be drawn by relating the inferences concerning the module-specific
parameters θk, say, the posterior distribution of θk, to the threshold δU . We will now define a formal
criterion as follows:
(i) A Go decision will be adopted for module k if P(θk > δU ) > ζ;
(ii) otherwise, a No-go will be taken.
This decision criterion consists of a probability threshold ζ ∈ [0, 1] to represent our confidence in the
advantages of the new treatment over the control. We note choices such as ζ = 0.90 may be appropriate
for the context. In what follows, we move on to present a novel analysis methodology to enable robust
borrowing of information between consistent modules of a basket trial.
3 Methods
In this section, we consider a formal incorporation of external module data into the analysis of a contem-
porary module in the Bayesian framework. Specifically, information from an external module will be used
to formulate a commensurate predictive prior (CPP), first proposed by Hobbs et al. (2011, 2012), for the
parameter that underpins the treatment effect in the module of the current analysis interest.
We suppose the patient-level trial data can be modelled using a linear regression in the form of (1),
and θk that underpins the treatment effect specific to a module is a continuous location parameter. Let
xk denote the data collected from module k. The information contained in module k can be represented
by a posterior distribution that is proportional to the product of the likelihood and an initial vague prior,
denoted by pi0k(θk):
pik(θk|xk) ∝ L(xk|θk)pi0k(θk). (2)
We label the module of our current analysis interest with k?. For estimating each θk? , there are (K − 1)
CPPs, each specified based upon xk from an external module k 6= k?, respectively. Following Hobbs
et al. (2011), we introduce a precision parameter, denoted by νkk? , which parameterises the consistency
between an external parameter θk and the target parameter θk? explicitly. Each of the CPPs for our
target parameter θk? , conditional on the knowledge about information consistency, can be given by
θk? |θk, νkk? ∼ N(θk, 1/ν2kk?), (3)
where θk is inferred from xk, and the precision νkk? would control the degree of borrowing. This then
leads to a CPP for θk? , jointly with the unknown precision νkk? :
piCPP(θk? , νkk? |xk, θk) ∝ L(xk|θk)pi0k(θk)× νkk?Φ((θk? − θk) · νkk?)gk(νkk?), (4)
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where Φ(·) is the standard normal probability density function, and gk(νkk?) is the prior for the one-to-
one precision νkk? that characterises the commensurability between modules k and k
?. If the external
module is consistent, i.e., given that ν2kk? is far greater than 0, the marginal CPP for θk? converges to
the posterior pik(θk|xk) that is updated from pi0k(θk), so that information contained in module k will be
largely incorporated.
A spike-and-slab distribution (Mitchell and Beauchamp, 1988) has been found suitable as a prior for
the normal precision (Hobbs et al., 2012, 2013). This is a discrete mixutre prior with two components,
which can provide us a means for robust borrowing. Specifically, it is defined as locally uniform between
two limits, 0 ≤ B1 < B2, except some portion of probability mass concentrated at a point, S > B2, such
that
P(νkk? < B1) = 0
P(νkk? < u) = wkk? · u− B1B2 − B1 , B1 ≤ u ≤ B2,
and P(νkk? > B2) = P(νkk? = S) = 1− wkk? ,
(5)
where wkk? is the probability that νkk? ∼ Unif(B1,B2). In situations of there being an external module k
with sufficiently consistent treatment effect, we expect strong borrowing of information from xk for esti-
mating θk? . This requires that the normal precision νkk? of the CPP take a large value, which is possible
when the “spike” prior has a large probability mass, that is, when wkk? is sufficiently small. Otherwise,
information should be down-weighted by allocating more probability mass to the “slab” prior. Instead of
setting a prior for wkk? , we propose linking it with a discrepancy measure, which quantifies the divergence
between the probability density distributions, pik(θk|xk) and pik?(θk? |xk?), arising from a same initial prior
pi0k(θk) and pi0k?(θk?) by including the module-wise data xk and xk? , respectively.
One viable option is the Hellinger distance (Dey and Birmiwal, 1994), which characterises discrepancy
between two probability densities, say, pik(θk|xk) and pik?(θk? |xk?):
dφH (piθk , piθk? ) =
√√√√1
2
∫ ∞
−∞
(√
dpik?(θk? |xk?)
dθ
−
√
dpik(θk|xk)
dθ
)2
dθ. (6)
Derivable from the Cauchy-Schwarz inequality, the computed Hellinger distance dφH (piθk , piθk? ) will strictly
fall into the interval of [0, 1], which is convenient for quantifying probability. We may then relate the “slab”
prior probability wkk? with the computed Hellinger distance, simply by stipulating wkk? = dφH (piθk , piθk? ).
In an extreme case that the evidence from the two modules are perfectly consistent, i.e., dφH (piθk , piθk? )→ 0,
the whole probability mass will be concentrated at the “spike”, S. In turn, this will result in a small nor-
mal variance 1/ν2kk? of the CPP in (4) such that the information from an external module k can be fully
incorporated. As well as these reasons for preferring the Hellinger distance to other distributional dis-
crepancy measures, it also has the desirable property of being invariant to any one-to-one transformation,
for example, logarithmic, exponential, or inverse of square root, of both densities (Jeffreys, 1961). Imag-
ine that the linear treatment-efficacy model in the form of (1) may be established using a different way
of parameterisation, where changes in the continuous outcome are explained by, say, the exponential of
the model parameter θk, the location invariant property ensures dφH (piθk , piθk? ) = dφH (piexp(θk), piexp(θk? )).
In other words, computing the Hellinger distance between the densities of θk and θk? truly informs the
discrepancy between the treatment effect on the clinical endpoint across patient subgroups.
We now turn our attention to combining the (K − 1) CPPs for obtaining a proper prior for our target
parameter θk? . As the CPPs are robust in that inconsistent information from any external module k
can be down-weighted through the “slab” prior, each is capable to describe well the parameter space of
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θk? . Recall that if values of the precision νkk? are appropriately specified, we may obtain (K − 1) normal
predictive priors marginally on θk? :∫
piCPP(θk? , νkk? |xk, θk)dνkk? ∝
∫
L(xk|θk)pi0k(θk)× νkk?Φ((θk? − θk)νkk?)gk(νkk?)dνkk? , (7)
where each one separately may be represented as a N(λk, ξ
2
k) distribution for the ease of notations. For
any θk? , there exist (K − 1) external modules as the sources where the possible values can be drawn
upon. We may thus see θk? as a weighted sum of random variables normally distributed with N(λk, ξ
2
k).
Specifically, the linear combination of (K − 1) terms is stipulated as
θk? =
K∑
k=1, k 6=k?
pkk? θ˜k, for k
? = 1, . . . ,K, (8)
where we suppose the hypothetical random variables θ˜k ∼ N(λk, ξ2k) and each set of the weights pk? =
(p1k? , p2k? , . . . ), containing (K − 1) elements, satisfies
∑
pk? = 1. This further gives
θk? |x(−k?) ∼ N
 K∑
k=1, k 6=k?
pkk?λk,
K∑
k=1, k 6=k?
p2kk?ξ
2
k
 , (9)
in which x(−k?) denotes the entire trial data collected from all modules except module k?. With this, one
is able to leverage information from multiple external modules. This marginal predictive prior, denoted
by piMPP(θk? |x(−k?)), is updated to the posterior, using the subtrial data from module k? as follows:
piMPP(θk? |xk? ,x(−k?)) ∝ L(xk? |θk?)× piMPP(θk? |x(−k?)). (10)
This allows decision making for module k?.
To determine the weight allocated to each external module, we expect pkk? to take a large value if
information from module k is consistent with module k?. Recall that we have used the Hellinger distance
to describe the pairwise commensurability of information between modules. Choices of these weights pkk?
may be guided by the computed pairwise Hellinger distance contained in a K ×K symmetric matrix:
0 d12 · · · d1K
d21 0 · · · d2K
...
...
. . .
...
dK1 dK2 · · · 0
 ,
where for ease of notation we have replaced dφH (piθk , piθk? ) by dkk? . We can break the distance matrix
into K vectors: each column k? = 1, . . . ,K describes the information consistency between θk? and θk,
for k 6= k?. These vectors can then be normalised into a series of weights pkk? ∈ [0, 1]. For this, we will
simply consider an analogue of the normal distribution likelihood by stipulating
pkk? =
exp(−dkk?/s0)∑
k exp(−dkk?/s0)
, (11)
where a pre-defined s0 governs how much influence the Hellinger distance has on the weight to be com-
puted. With a very large value s0 → ∞, nearly the same weight will be allocated irrespective of the
pairwise Hellinger distance that could be very different from each other. Whereas, with s0 → 0+, the
weight corresponding to a Hellinger distance close to 0 tends to be 1. Weights converted from the pairwise
Hellinger distance following (11) can then be used to weight each θ˜k, as was stipulated in (8).
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We would like to add one more note here. The stipulation of weights pkk? summing to 1 does not
restrict the potential of full borrowing of information in stiuations, where all the (K−1) external modules
are perfectly consitent with module k?. In such a scenario, the Hellinger distance dkk? = 0, suggesting
that the CPPs marginally on θk? , represented by N(λk, ξ
2
k), have identical mean and variance to those
of pik?(θk? |xk?). Moreover, equal weights, i.e., pkk? = 1K−1 , will be allocated to the modules external to
module k?, respectively. Following (9), a predictive prior piMPP(θk? |x(−k?)) would be obtained with its
mean as λk and variance as
1
K−1ξ
2
k. With the inclusion of xk? , the posterior mean and variance become
λk and
1
K ξ
2
k, respectively. This indicates the external module data x(−k?) have been fully incorporated,
and our methodology converges to the approach of complete pooling in the case of perfect information
consistency.
4 Simulation study
In this section, we illustrate applications of the proposed analysis methodology, and compare it with
alternative Bayesian models that may be used for analysing basket trials through a simulation study.
Our trial examples are hypothetical, but can represent the situation of a phase II basket trial, for which
the analyses are performed to enable sharing of information. The main characteristics of the study we
simulate are based on the motivating PBC and PD trial described in Section 2. For illustrative purposes,
we assume six modules instead of three, as typically a fairly large number of patient subgroups would be
examined; see, for example, Hyman et al. (2015) and Hyman et al. (2018) which report the results from
basket trials with six and nine modules, respectively.
4.1 Basic settings
We simulate basket trials with K = 6 modules of unequal sample sizes: nk ∈ {10, 14, 10, 20, 16, 20},
respectively. Within each module, patients are allocated equally to receive the new treatment or a placebo.
We simulate two covariates for each patient as zik1 ∼ N(6, 0.12) and zik2 ∼ N(4, 0.12), for i = 1, . . . , 90.
In particular, zik1 is assumed to be the baseline measurement of the endpoint of clinical interest at the
time of randomisation. We generate the trial data from a linear regression: for i = 1, . . . , 90, k = 1, . . . , 6,
yik ∼ N(ηik, σ2) i.i.d.
ηik = zik1γ1k + zik2γ2k + Tikθk,
(12)
where we set the “true” parameter values for effect of covariates to γ1k = 1 and γ2k = 1.3, and σ = 0.2.
It is optional to borrow information across modules or not at all for estimating the module-specific
parameters other than θk. Throughout, we consider random effects for γ1k and γ2k (thus information is
also shared for estimating these coefficients):
γ1k = χ1 + 
2
1 and γ2k = χ2 + 
2
2,
where inverse gamma priors Γ−1(0.001, 0.001) are used for the variances 21 and 22 that account for the
between-module heterogeneity, respectively. For χ1 and χ2, an uninformative normal prior N(0, 10
2) is
placed on each.
To implement our methodology for estimating θk, we choose setting B1 = 0.001, B2 = 10 and S = 100
for the spike-and-slab prior on each νkk? . The “slab” prior is thus very uninformative, and the “spike”
prior would essentially lead to a full incorporation of subtrial data from an external module in situations
of perfect information commensurability. An initial vague prior pi0k(θk) is used for θk, k = 1, . . . , 6; we use
N(0, 102) such that the prior mean, together with the 95% credible interval, is 0 (-19.560, 19.560), covering
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a wide range of possible θk. To yield a large (small) weight pkk? corresponding to a small (large) Hellinger
distance, we let s0 = 0.1 to combine information from all available modules. Whilst θk would have been
estimated using alternative Bayesian analysis models, we are interested in comparing the performance of
our methodology with
1. Standard hierarchical model (HM) that assumes fully exchangeable parameters: θk|µ,τ ∼ N(µ, τ2)
with µ ∼ N(0, 12) and τ ∼ HN(0.25). Here, HN(z) is a half-normal distribution, defined as a
N(0, z2) truncated to cover the interval (0,∞). The use of a half-normal prior is consistent with the
findings written by Cunanan et al. (2019).
2. Bayesian model with no borrowing of information. Trial data are stratified by modules for stand-
alone analyses, setting each θk ∼ N(0, 102). Since random effects for γ1k and γ2k cannot be estimated
due to the stratification, we stipulate an uninformative prior N(0, 102) on each for implementation.
3. EXNEX model by Neuenschwander et al. (2016), with equal prior probabilities of exchangeability
(EX) and non-exchangeability (NEX). The EX distribution has the same parameter configuration
as what was stipulated for the standard HM above, and the six NEX distributions are all set to be
N(0, 102).
Comparison is in terms of the precision of their posterior point estimates, more specifically, the pos-
terior means, for θk that could be measured by an analogue of bias and mean squared error (MSE):
Bias(θk) ≈ 1
M
M∑
m=1
θ¯mk − θk,
MSE(θk) ≈ 1
M
M∑
m=1
(θ¯mk − θk)2,
where M represents the total number of replicates in the simulation study, and θ¯mk denote the posterior
means of θk for the m-th simulated basket trial. These metrics will be reported by module. We also
compare these Bayesian analysis models with respect to the trial operating characteristics, such as the
module-wise error rates. Corresponding to the frequentist type I error rate and statistical power, we will
report proportions of the simulated trials with
• an erroneous Go decision in a module for the “true” θk ∈ (−∞, 0], and
• a correct Go decision in a module for the “true” θk > 0,
respectively.
Eight simulation scenarios are evaluated with the treatment effect θk varying between 0 and 1.38.
Table 1 lists these simulation scenarios, which reflect varying degrees of heterogeneity on the treatment
effect across modules. We note that all sets of the “true” values of θk are realisations from distinct multi-
variate normal distributions, where we stipulate a high pairwise correlation coefficient (0.8) for θk of the
consistent modules and a low pairwise correlation coefficient (0.1) between θk of an extreme module and
of one else from the rest. We highlight the modules with a 0 or low treatment effect (0 < θk ≤ 0.35). By
way of contrast, in the global null scenario we set all θk = 0. Scenarios 7 and 8 can be seen as “mixed
null” scenarios. In such scenarios, we may be particularly interested in the proportion of trials with an
erroneous Go decision for modules with a zero treatment effect. We note that the computed module-wise
error rates are subject to the decision criterion. For example, the error rates would differ by varying the
value of the bound δU , above which the new treatment is concluded to be superior than a placebo.
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Each of the four Bayesian analysis models will be applied to analyse every simulated basket trial.
Decision making on a Go versus No-go for every module is based on the entire posterior distribution for θk.
More specifically, a module is allocated with a Go decision if the interval probability P(θk > 0.25) > 0.90,
and a No-go otherwise. Results will be summarised by averaging across 1000 replicates of the hypothetical
basket trial by module. The Bayesian analysis models are implemented in R version 3.4.4 using the
R2OpenBUGS package based on two parallel chains, with each running the Gibbs sampler for 10,000
iterations that follow a burn-in of 3000 iterations. OpenBUGS code, together with R functions, to
implement each of the Bayesian analysis models is available at https://github.com/BasketTrials/
Bayesian-analysis-models.
4.2 Results
Figure 1 compares the performances of the posterior estimators based upon the four Bayesian models. It
shows that the proposed analysis methodology produces smaller bias and MSE than the standard HM and
EXNEX, across nearly all simulation scenarios. Point estimators based on the standard HM and EXNEX
work well in scenarios 1, 5 and 6, as the small-to-moderate variability between θks can be addressed by
setting τ ∼ HN(0.25). The proposed analysis methodology, in contrast, distinguishes the heterogeneity
more sensitively. Much smaller bias and MSE are yielded when estimating the low treatment effect, for ex-
ample, in modules 1 and 3, regardless of the large treatment effect in module 4 of scenario 2. In situations
where information from other modules should be largely discounted, referring to modules in scenarios 7
and 8, our methodology generates similar bias to the no borrowing approach but, overall, with a smaller
MSE. This is because information from modules with a non-zero treatment effect, for example, in scenario
8, can be largely discounted to formulate the marginal predictive priors for θ3 and θ4. Not surprisingly, less
borrowing of information in scenarios with extreme subgroups results in characteristics more comparable
to those of the trials that would have been analysed using the no borrowing approach. This explains why
our approach and the no borrowing approach outperform the standard HM and EXNEX in some scenarios.
We have also compared the Bayesian analysis models in terms of the average width of the posterior
credible intervals for θk obtained based on each of the four analysis models. In contrast to the alternative
Bayesian models, the proposed methodology yields posterior estimates with narrower credible intervals
when there is at least one consistent external module in the same trial. Such results are summarised in
Figure S1 of the Supplementary Materials. When using the proposed analysis methodology for borrowing
of information, investigators may be interested in the weight eventually allocated to each external module
for obtaining the marginal predictive prior. In Figure S2 of the Supplementary Material, we comment
with regards to scenarios 4 and 5 on the weight allocation based on the assessed pairwise commensurability.
Table 2 quantifies the impact of using different Bayesian models on the error rate control under the
null hypothesis. For the global null scenario, where we have simulated the trial data setting “true” θk = 0,
all the four Bayesian analysis models control the error rate well. Nevertheless, the approaches that en-
able borrowing of information, i.e., standard HM, EXNEX and the proposed methodology, have smaller
chances to adopt an incorrect Go, when compared with the approach of no borrowing, since incorporating
consistent information from external modules reassures the investigator that P(θk > 0.25) > 0.90 highly
unlikely. Our approach produces slightly higher error rates than standard HM and EXNEX, as for some
simulated trials information from modules with a similar low treatment effect may be shared, leading to
a higher chance to reject the null θk’s. In scenario 8 where some modules have large treatment effect,
we observe substantial inflation of the error rate for trials analysed using the standard HM approach and
moderate inflation for trials using EXNEX. Due to the We note that a difference in the sample sizes of
modules 3 and 4 (for all scenarios) leads to disparate performances of the same approach in the same
scenario with null θk’s. More explicitly, when reacting to a prior-data conflict, a larger sample size of
module 4 provides more evidence to evaluate the plausibility of down-weighting; estimation of θ4 may
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thus have more chances to avoid being overwhelmed by external information.
What may be more interesting to investigators is the potential increase in statistical power to demon-
strate the treatment effect, by incorporating information from external modules. Figure 2 visualises the
comparison of the Bayesian analysis models in terms of correctly declaring a clinical benefit in module
k. Across nearly all the modules of the simulated basket trials in scenarios except 6 and 7, the Bayesian
approaches of borrowing show substantial advantages over the approach of no borrowing. When compar-
ing between the Bayesian approaches of borrowing, we may be particularly interested in checking how the
chance would be for a module with low treatment effect to be concluded with a correct Go decision. For
example, for modules 1, 4 and 6 in scenario 3 as well as module 4 in scenario 4, our approach presents
very similar behaviours to EXNEX, while standard HM implements strong borrowing of information for
there being more than one module with large treatment effect.
For all modules of the simulated trials in scenarios 5 and 6, our approach outperforms both standard
HM and EXNEX for leveraging the consistent information from all external modules. Given our criterion
that only P(θk > 0.25) > 0.90 will result in a Go decision, we note scenario 6, under which the trial data
are simulated setting θk = 0.30, is particularly a hard scenario. Using the approach of no borrowing seems
to yield slightly higher proportion of the basket trials with a correct Go decision, compared with standard
HM and EXNEX. However, this does not mean the no borrowing approach is more powerful. Instead,
standard HM and EXNEX produce estimates of θk with smaller posterior variances than the approach of
no borrowing, as we may observe from Panel (ii) of Figure 1 and Figure S1 of the Supplementary Mate-
rials. Nevertheless, it is possible that the interval probability computed using the no borrowing approach
with a diffuse prior for θk has comparable or even slightly higher chances to exceed the level γ = 0.90.
The proposed approach, however, can implement effective borrowing of information in such situations due
to the use of Hellinger distance, which characterises commensurability of the trial data across modules.
When the consistent “true” θks increase from 0.30 (scenario 6) to 0.45 (scenario 5), we see more advan-
tages of implementing Bayesian models that permit borrowing of information than no borrowing, whilst
our approach still appears to be superior to its alternatives.
In scenario 7, due to the prior specification of τ ∼ HN(0.25) being capable of accounting for the
variability across modules, both standard HM and EXNEX may shrink θ5 and θ6 excessively towards the
population mean. This in turn dilutes the treatment effect in corresponding modules. Consequently, it
appears to be better to implement the approach of no borrowing rather than standard HM or EXNEX: at
least the former would not miss the chance to identify the treatment effect. Our approach presents slightly
higher power than the no borrowing approach as there is some consistent information to be incorporated
from an external module. In scenario 8, our approach performs similarly to the no borrowing approach
for module 1, as information from all other modules is largely discounted, but slightly better than its
comparators for modules 2, 5 and 6 due to incorporation of consistent information from external modules.
Standard HM and EXNEX improve the statistical power for module 1, in the presence of strong treatment
effects in modules 2, 5 and 6. However, this sacrifices the type I error rate control for modules 3 and 4.
5 Discussion
The paradigm shift towards precision medicine opens new avenues for novel trial designs and analysis
methodologies to deliver more tailored healthcare to patients. Basket trials emerge as a new class of effi-
cient approaches to drug development in the era of precision medicine, offering a framework to evaluate
the treatment effect together with its heterogeneity in various patient subgroups. In this paper, we have
presented a commensurate prior approach for basket trials to make good use of the trial data collected from
multiple modules without requiring a priori clustering of similar subgroups. By including an information
discrepancy measure, it can discern the degree of borrowing from other subgroups to improve inferences
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in one that is of local analysis interest. In particular, the Hellinger distance plays a dual role in our
methodology: (i) it gauges the maximum amount of information that could be leveraged from an external
module k 6= k? when estimating the target parameter θk? ; (ii) when there are K ≥ 3 modules, it deter-
mines the weight allocation to external modules so that the relative importance could be properly reflected.
The Bayesian analysis methodology in Section 3 has been developed assuming the basket trial gen-
erates continuous response data. However, it could be easily generalised to analyse other types of data
that can be fitted using a generalized linear model for non-Gaussian error distributions. For example, it
would be readily applicable to analysing phase II basket trials that use binary endpoints: after fitting the
patient-level data per module with a logistic regression model, our approach may be considered to stipu-
late commensurate predictive priors, informed by the pairwise Hellinger distance, for the module-specific
parameters to discuss borrowing of information from the most consistent modules. For down-weighting in
cases of data conflict suggested by the Hellinger distance, we did not delve into calibration of the “slab”
prior but simply use a very uninformative uniform prior for the normal precision. As this could be quite
relevant to the investigation by Mutsvari et al. (2016) about choosing the diffuse component of a mixture
prior for robust inferences, we believe it is worth further research on the performance of our approach.
The exploration may be closely linked with the users’ stipulation of the probability weight, which is based
upon the Hellinger distance, to be attributed to the “slab” prior.
In our simulation study, we have considered imbalance module sizes. Simulation results show that
our methodology can down-weight inconsistent information from a module that has larger sample sizes.
For illustrative purposes, we have supposed equal randomisation ratio between treatment groups within
a module. Investigators can pragmatically determine the randomisation ratio as well as the module-wise
sample size for a basket trial that may base decision making on our analysis methodology. Potentially,
more dosage groups of the same treatment in each module can be considered. Also, many have shown
a great interest in sequential basket trials (Simon et al., 2016; Cunanan et al., 2017; Hobbs and Landin,
2018) with interim look(s) incorporated for possibility of, say, terminating enrollment of patients in in-
effective subgroups. We note the proposed Bayesian approach can be implemented with any number of
analyses following a flexible timescale for interim decision making. There is no requirement of a minimum
sample size per module to carry out an interim look, due to the use of an initial vague prior pi0k(θk) for
the subgroup-specific model parameter for computing the pairwise Hellinger distance.
Throughout, we have restricted our focus onto basket trials, where the subtrials use the same endpoint
across patient subgroups. However, in many diseas areas multiple endpoints (FDA, 2017) may often arise,
as it could involve various dimensions to conclude on the clinical benefit. One common situation is to
continue monitoring toxicity in addition to the assessment of efficacy (Bryant and Day, 1995; Tournoux
et al., 2007). With regards to this, our approach could be extended in several ways. For instance, in cases
where the set of multiple endpoints remain the same across subgroups, it would be straightforward to
establish a joint probability model and derive the pairwise Hellinger distance between multivariate prob-
ability densities (Pardo, 2005). Suitable alternatives include separating the discussion about borrowing
of information by endpoint. A unified utility function may then be adopted for trial decision making
based on evidence on multiple endpoints. In another more complex setting where the efficacy endpoint,
for example, could be distinct but correlated across subgroups, one might need to translate the subtrial
data onto a common scale in order to adapt the presented approach. Ideas could be drawn from Zheng
et al. (2019), where incorporation of external data recorded on a different measurement scale has been
discussed in the context of phase I clinical trials.
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Figure 1: Bias and mean squared error of the module-wise estimators for θk based on the four Bayesian
analysis models, respectively.
12
Scenario 5 Scenario 6 Scenario 7 Scenario 8
Scenario 1 Scenario 2 Scenario 3 Scenario 4
1 2 3 4 5 6 1 2 3 4 5 6 1 2 3 4 5 6 1 2 3 4 5 6
0.0
0.2
0.4
0.6
0.8
1.0
0.0
0.2
0.4
0.6
0.8
1.0
Module
Pr
op
or
tio
n 
of
 tr
ia
ls
 w
ith
 a
 c
or
re
ct
 G
o 
un
de
r H
a
Standard HM No borrowing EXNEX Proposed approach
Figure 2: Comparison of the Bayesian analysis models with respect to the analogue of statistical power:
null hypothesis is correctly rejected in the presence of a treatment effect per module.
Table 1: Simulation scenarios with specification of the ‘true’ treatment effect θk to compare the Bayesian
analysis models. The figure in bold indicates a 0 or low treatment effect.
Module k (Sample size, nk)
Scenario 1 (n1 = 10) 2 (n2 = 14) 3 (n3 = 10) 4 (n4 = 20) 5 (n5 = 16) 6 (n6 = 20)
1 0.49 0.54 0.67 0.39 0.43 0.35
2 0.35 0.80 0.37 1.38 0.69 0.40
3 0.29 0.68 0.77 0.33 0.75 0.30
4 0.59 1.02 1.17 0.13 0.95 0.75
5 0.45 0.45 0.45 0.45 0.45 0.45
6 0.30 0.30 0.30 0.30 0.30 0.30
7 0 0 0 0 0.37 0.37
8 0.33 0.82 0 0 0.90 0.83
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Table 2: Comparison of the Bayesian analysis models with respect to the analogue of type I error rate:
null hypothesis is erroneously rejected under scenarios of any θk ∈ (−∞, 0].
Module
1 2 3 4 5 6
Global null Standard HM 0.001 0.000 0.000 0.000 0.000 0.000
No borrowing 0.015 0.013 0.020 0.007 0.006 0.001
EXNEX 0.002 0.000 0.000 0.000 0.000 0.000
Proposed approach 0.005 0.006 0.010 0.002 0.003 0.007
Scenario 7 Standard HM 0.001 0.000 0.000 0.000 - -
No borrowing 0.015 0.013 0.020 0.007 - -
EXNEX 0.002 0.000 0.000 0.000 - -
Proposed approach 0.027 0.012 0.020 0.007 - -
Scenario 8 Standard HM - - 0.353 0.250 - -
No borrowing - - 0.044 0.007 - -
EXNEX - - 0.251 0.056 - -
Proposed approach - - 0.073 0.015 - -
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Web-based Supplementary Materials for:
Borrowing of information across subpopulations in a
basket trial based on distributional discrepancy
by Haiyan Zheng, James M.S. Wason
A. ADDITIONAL SIMULATION RESULTS
In addition to the bias and MSE comparisons in Section 4, we consider reporting the width of
the 95% posterior credible intervals (CIs) for θk yielded by the Bayesian analysis models to give a
general sense how precise the posterior estimates are. Averaging across the 1000 simulated basket
trials by module, Figure S1 graphically represents the median width of the 95% posterior CIs
using height of the bars, together with the 10th and 90th percentiles using endpoints of the error
bars. We observe that the approach of no borrowing results in the widest posterior CIs across all
scenarios. In contrast, the proposed approach of borrowing based on distributional discrepancy
generates the narrowest posterior module-wise estimates, when there exist at least one module
with commensurate treatment effect. In scenarios of information consistency across all modules,
such as scenarios 5 and 6, the proposed approach outperforms the competing Bayesian models by
producing the narrowest posterior CIs, together with the nearly unbiased posterior means shown
in Figure 1 of the main paper. In some scenarios such as modules 1 and 6 in scenario 2 and module
1 in scenario 8, the proposed approach leads to posterior CIs of comparable widths with those of
EXNEX or standard HM, but much longer error bars. This suggests that our approach may be
highly sensitive to the disparate treatment effect on subgroups demonstrated by trial data.
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Figure S1: Summaries about the width of the posterior 95% posterior credible interval for θk , estimated using each of the Bayesian
analysis models.
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It would be interesting to see how well the proposed approach can differentiate borrowing of
information from other subgroups when the treatment effect is disparate across patient subgroups.
Specifically, we expect it can (i) identify the most consistent subgroup(s) and, accordingly, allocate
the largest weight(s) in a scenario of heterogeneous treatment effect, and (ii) weight the subgroups
equally in a scenario of consistent treatment effect.
Figure S2 gives an overview about the weight allocation, which is a function of the computed
pairwise commensurability, for scenarios 4 (some subgroups are more similar between themselves
than with others) and 5 (equally similar). The subfigures show our approach can correctly identify
the most consistent subgroups. Referring to Subfigure S2(a) for the weight allocation to external
modules given their pairwise commensurability with module 3, the medians suggest the order
is: module 2, module 5, module 6, module 1 and module 4, which is consistent with the assessed
pairwise commensurability of information. Nevertheless, summarising across the 1000 simulated
basket trials, we see the interquartile range of the weight allocated to module 2 is much larger
than the pairwise commensurability for module 2 and module 3 in the same plot. This is because
the pairwise commensurability concerns only the information between any two modules, whilst
the normalised weights are computed based on all the pairwise commensurability measurements
due to our stipulation. In other words, the weight allocated to each module reflects the relative
importance of a corresponding subgroup for offering strength to borrow. When the weights allo-
cated to other modules are variable, the weight to module 2 will inevitably be affected. Referring
to Subfigure S2(b) for the weight allocation in situations of equally consistant, we observe that the
weight allocation is highly balanced. Due to there being K = 6 modules, the weights allocated to
external modules are concentrated at 20%, which is 1/(K − 1). When all the subgroups demon-
strate the same treatment effect, meaning that all external subgroups are equally important, equal
weights would be assigned correspondingly, as is shown in Subfigure S2(b).
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Figure S2: Boxplots of the weight allocation to all external modules (q 6= k) for leveraging only the most consistent information in the
module k of current analysis interest. Subfigure (a) visualises the simulation results of scenario 4, and subfigure (b) of scenario 5. The
dashed line indicate the weight of 20%.
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B. LEVERAGING INFORMATION FROM THEMOST CONSISTENT SUBGROUP(S)
We believe it would be helpful to show how Hellinger distance can pick up the most consistent
subgroup(s) by visualising the marginal prior for a target parameter θk? , piMPP(θk? |x−k?), through
some hypothetical data examples.
We will use the ‘true’ θk in scenarios 4 and 5 to simulate two datasets, representing situations
where (i) some subgroups demonstrate more similar treatment effect between themselves than
with others, and (ii) all subgroups demonstrate equally similar treatment effect. In particular, we
expect our approach to effectively identify two cliques given the dataset simulated from setting
θk = (0.59, 1.02, 1.17, 0.13, 0.95, 0.75), potentially with θ2, θ3 and θ5 constituting a clique.
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Figure S3: Update of the marginal predictive priors for θk to their marginal posterior, using the proposed methodology for borrowing
of information from consistent modules. Subfigures (a) and (b) correspond to the situations of (i) varying treatment effect and (ii)
equally similar treatment effect, respectively.
Figure S3 visualises the marginal predictive priors for the target parameters θk? and how these
piMPP(θk? |x−k?) would be updated to the posteriors. As we can see, the marginal predictive priors
for θ2, θ3 and θ5 appear to be more informative than those for θ1 and θ4 within Subfigure S3(a),
for there being consistent subgroups for information sharing. The marginal prior for θ4 is centred
around θk = 0.59, suggesting that module 1 has been picked as (relatively) the most consistent
subgroup while information from other modules will be largely discounted. Due to the use of
spike-and-slab prior, the posterior for θ4 is bimodal, when there is a prior-data conflict. Comparing
Subfigure S3(b) with Subfigure S3(a), we observe more informative marginal priors have been
formed due to information commensurability and each posterior become more informative by
including data from all external, consistent modules.
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